Sanofi: New long-term data reinforcing promising safety and

New long-term data reinforcing promising safety and efficacy profile of brain-penetrant tolebrutinib presented at ECTRIMS 2021 One-year results from Phase 2b extension study of brain-penetrant tolebrutinib

Related Keywords

United States , Paris , France General , France , United Kingdom , America , British , Eva Schaefer Jansen , Erik Wallstr , Arnaud Delepine , Anthony Traboulsee , Felix Lauscher , Nathalie Pham , Sally Bain , Neurology Development At Sanofi , Research In Multiple Sclerosis , European Committee For Treatment , European Committee , Multiple Sclerosis , Therapeutic Area Head , Neurology Development , Research Chair , British Columbia , Extension Study , Efficacy Outcomes , Expanded Disability Status Scale , Private Securities Litigation Reform Act , Statement Regarding Forward Looking , Sanofi , Song , Term , Data , Reinforcing , Romising , Safety , Efficacy , Profile , Rain , Penetrant , Tolebrutinib , Resented , Actrims , 021 ,